Skip to main content

Table 5 Guideline characteristics within GI tool categories

From: Number and type of guideline implementation tools varies by guideline, clinical condition, country of origin, and type of developer organization: content analysis of guidelines

Guideline characteristic (n GI tools) GI tool category (n, %)
Patient Clinician Implementation Evaluation
Overall (464) 113 (24.4) 239 (51.5) 66 (14.2) 46 (9.9)
Condition
 Diabetes 37 (32.7) 64 (26.8) 20 (30.3) 9 (19.6)
 Stroke 26 (23.0) 63 (26.4) 8 (12.1) 3 (6.5)
 Heart failure 15 (13.3) 48 (20.1) 14 (21.2) 11 (23.9)
 Asthma 15 (13.3) 30 (12.6) 4 (6.1) 1 (2.2)
 Arthritis 12 (10.6) 13 (5.4) 6 (9.1) 4 (8.7)
 Depression 5 (4.4) 20 (8.4) 10 (15.2) 7 (15.2)
 Colorectal cancer 3 (2.7) 1 (0.4) 4 (6.1) 11 (23.9)
Country
 United States 62 (54.9) 121 (50.6) 16 (24.2) 0 (0.0)
 United Kingdom 28 (24.8) 38 (15.9) 41 (62.1) 44 (95.7)
 Canada 21 (18.6) 60 (25.1) 8 (12.1) 1 (2.2)
 Australia 1 (0.9) 9 (3.8) 0 (0.0) 1 (2.2)
 International group 1 (0.9) 7 (2.9) 0 (0.0) 0 (0.0)
 Singapore 0 (0.0) 2 (0.8) 1 (1.5) 0 (0.0)
 Brazil 0 (0.0) 2 (0.8) 0 (0.0) 0 (0.0)
 Finland 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
 Spain 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Organization
 Government agency 39 (34.5) 48 (20.1) 40 (60.6) 39 (84.8)
 Professional society 23 (20.4) 97 (40.6) 13 (19.7) 2 (4.3)
 Disease foundation 18 (15.9) 37 (15.5) 4 (6.1) 4 (8.7)
 Academic institution 29 (25.7) 31 (13.0) 6 (9.1) 0 (0.0)
 Non-profit agency 4 (3.5) 25 (10.5) 3 (4.5) 1 (2.2)
 International group 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0)
  1. In contrast to Table 4, the proportion of GI tools reflects the total number of GI tools in each category (patient, clinician, implementation, evaluation)